Oric Pharmaceuticals, Inc.(ORIC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ORIC Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Oric Pharmaceuticals, Inc. (ORIC), a Healthcare sector company. ORIC is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Oric Pharmaceuticals, Inc. reports net income of $-41.5M, free cash flow of $-32.0M. Top institutional holders of ORIC by reported 13-F value include Nextech Invest, Ltd., BlackRock, EcoR1 Capital, based on the most recent SEC filings. ORIC trades on the Nasdaq exchange and files with the SEC under CIK 1796280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORIC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Oric Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-41.5M
Free Cash Flow
Q2 2026
$-32.0M
ROIC
Q2 2026
-47.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-1.3% YoYOperating Income
-0.1% YoYEPS (Diluted)
+19.7% YoYTotal Assets
+49.2% YoYTotal Debt
Op. Cash Flow
+1.5% YoYFree Cash Flow
+1.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-129.5M -1.3% | $-127.8M -27.0% | $-100.7M -13.0% | $-89.1M -13.2% | $-78.7M -6.8% | $-73.7M |
| Operating Income | $-143.0M -0.1% | $-142.9M -29.0% | $-110.8M -20.7% | $-91.8M -16.4% | $-78.9M -6.3% | $-74.2M |
| EPS (Diluted) | $-1.47 +19.7% | $-1.83 +6.6% | $-1.96 +12.9% | $-2.25 -8.7% | $-2.07 | — |
| Total Assets | $408.9M +49.2% | $274.1M +8.8% | $252.0M +2.0% | $247.2M -17.2% | $298.6M -0.1% | $299.0M |
| Total Debt | — | — | — | — | $10.5M +1650.0% | $600.0K |
| Operating Cash Flow | $-111.0M +1.5% | $-112.7M -31.5% | $-85.7M -14.0% | $-75.1M -26.2% | $-59.5M -31.5% | $-45.3M |
| Free Cash Flow | $-111.7M +1.9% | $-113.8M -31.6% | $-86.5M -12.1% | $-77.2M -27.7% | $-60.5M -31.7% | $-45.9M |
Get alerted when ORIC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Oric Pharmaceuticals, Inc. including:
Top Institutional Holders of ORIC
Nextech Invest, Ltd.
$77.6M7,162,637 shBlackRock, Inc.
$73.9M6,823,973 shEcoR1 Capital, LLC
$72.9M6,728,116 shPRICE T ROWE ASSOCIATES INC /MD/
$71.7M6,617,554 shVIKING GLOBAL INVESTORS LP
$55.5M5,126,762 shSTATE STREET CORP
$53.0M4,894,000 shSR ONE CAPITAL MANAGEMENT, LP
$50.0M4,615,384 shVR Adviser, LLC
$46.8M4,319,765 shNEA Management Company, LLC
$44.6M4,118,621 shVANGUARD CAPITAL MANAGEMENT LLC
$42.8M3,951,169 sh
| Fund | Value | Shares |
|---|---|---|
| Nextech Invest, Ltd. | $77.6M | 7,162,637 |
| BlackRock, Inc. | $73.9M | 6,823,973 |
| EcoR1 Capital, LLC | $72.9M | 6,728,116 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $71.7M | 6,617,554 |
| VIKING GLOBAL INVESTORS LP | $55.5M | 5,126,762 |
| STATE STREET CORP | $53.0M | 4,894,000 |
| SR ONE CAPITAL MANAGEMENT, LP | $50.0M | 4,615,384 |
| VR Adviser, LLC | $46.8M | 4,319,765 |
| NEA Management Company, LLC | $44.6M | 4,118,621 |
| VANGUARD CAPITAL MANAGEMENT LLC | $42.8M | 3,951,169 |
More Healthcare Companies
View all Healthcare →Put ORIC on your watchlist
Track score changes the day Oric Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ORIC a good stock to buy?
13F Pro's AI-powered analysis of Oric Pharmaceuticals, Inc. (ORIC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ORIC are available on the ORIC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ORIC is classified as a small company.
Which hedge funds own ORIC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ORIC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Oric Pharmaceuticals, Inc.'s investment landscape.